Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers

The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in healthy volunteers.

Inclusion Criteria:

• Informed Consent
• Male or female subjects 18-45 years of age
• General good health

Exclusion Criteria:

• History of physical findings of nasal pathology (within 60 days prior to Screening Visit)
• Participation in any investigational drug study 30 days preceding Screening Visit
• History of respiratory infection/disorder with 28 days preceding Screening Visit